Prothena Corp Plc (PRTA): Karin L Walker , officer of Prothena Corp Plc sold 12,000 shares on Sep 19, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $60.92 per share for a total value of $733,203.81 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 2, 2016, Arthur W Homan (Chief Legal Officer) sold 3,125 shares at $52.16 per share price.On Aug 24, 2016, Dennis J. Selkoe (director) sold 5,000 shares at $54.72 per share price.Also, On Aug 5, 2016, Christopher S Henney (director) sold 10,000 shares at $63.21 per share price.On Apr 15, 2016, Karin L Walker (officer ) sold 4,000 shares at $45.23 per share price.
Prothena Corporation PLC: On Tuesday, Sep 21, 2016 heightened volatility was witnessed in Prothena Corporation PLC which led to swings in the share price. The shares opened for trading at $62.19 and hit $62.91 on the upside , eventually ending the session at $61.42, with a gain of 0.52% or 0.32 points. The heightened volatility saw the trading volume jump to 3,29,489 shares. The 52-week high of the share price is $76.42 and the company has a market cap of $2,113 M . The 52-week low of the share price is at $28.2.
Company has been under the radar of several Street Analysts.Prothena Corporation PLC is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 70 from a previous price target of $60 .The Rating was issued on Aug 4, 2016.
Prothena Corporation Public Limited Company is an Ireland-based late-stage clinical biotechnology company. The Company is focused on the discovery development and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. The Company’s research and development pipeline includes three therapeutic antibody programs such as NEOD001 for the treatment of AL amyloidosis; PRX002 in collaboration with Roche for the treatment of Parkinson’s disease and other related synucleinopathies and PRX003 for the treatment of psoriasis and other inflammatory diseases. The Company’s pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of diseases related to amyloid or cell adhesion.